Molecular Imaging Lab | Flavell Lab

---

Research Laboratory of Robert Flavell, MD, PhD

• Assistant Professional Researcher – Molecular Imaging and Therapy
  Department of Radiology and Biomedical Imaging, University of California-San Francisco, United States
• Postdoctoral scholar (II) – Molecular Imaging and Therapy
  Department of Radiology and Biomedical Imaging, University of California-San Francisco, United States
• Postdoctoral scholar (I) – Molecular and Cellular Biophotonics
  Department of Bioengineering, University of California-Berkeley, United States
• Ph.D. – Inorganic Therapeutics and Magnetic Resonance Spectroscopy
  Department of Chemistry, Simon Fraser University, Vancouver, Canada
• M.Sc. – Analytical Science and Instrumentation
  Department of Chemistry, University of Warwick, Coventry, England
• B.Sc. – Chemistry and Chemical Engineering
  Department of Chemistry and Chemical Engineering, Shandong University, Jinan, China

Dr. Anju Wadhwa is a Postdoctoral Fellow in the Department of Radiology and Biomedical Imaging. She achieved her doctoral degree from the Department of Chemistry, University of Delhi, India. During her graduate studies, her research primarily centered on the design and development of metal complexes as molecular imaging probes and the application of molecular probes for the diagnosis of prostate cancer and breast cancer. Dr. Wadhwa is currently working on the development of theranostics for hematological malignancy Multiple Myeloma and Acute Myeloid Leukemia.

Athira Raveendran had completed her Bachelor's degree in Biochemistry from India (2018) and a Ph.D. in Advanced Bioengineering from Chonnam National University, South Korea (2023). Currently, working as a post-doctoral researcher in Prof. Robert Flavell’s group at UCSF. Her research focuses on the the dynamic and cutting-edge field of radiopharmaceuticals, with a particular focus on advancing both radioligand therapy and imaging modalities like PET/SPECT to improve cancer detection and treatment. The research also involves the integration of PARP inhibitors with radionuclide therapy, demonstrating an approach that promises enhanced therapeutic outcomes.